Indeed in melanoma patients, the association of anti-PD-1 with anti-VEGF has proved futile (LEAP-003 trial) [54], suggesting that tumor selection and patient stratification, according to the immunological targets, is crucial. This evidence concerns the gene PDCD1 and melanoma.